Application of manganese-doped iron oxide nanoparticles in preparation of anti-tumor drug and anti-tumor drug
By using manganese-doped iron oxide nanoparticles and nonionic surfactants in sound-sensitive agents, the shortcomings of existing sound-sensitive agents in clinical applications have been solved, and the efficient release of reactive oxygen species has been achieved, which has significantly improved the use of triple-negative breast cancer. Treatment effect.
Patent Information
- Application Number
- CN202410886163.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-03
- Publication Date
- 2024-11-19
AI Technical Summary
Existing sound-sensitizers have problems such as phototoxicity, poor water solubility, insufficient utilization rate and hypoxic tumor microenvironment in clinical applications, resulting in poor effect of ultrasound-triggered acoustic dynamics therapy (SDT) and it is difficult to effectively inhibit triple-negative breast cancer. metastasis and recurrence.
Manganese-doped iron oxide nanoparticles are used to adsorb non-ionic surfactants, such as polyethylene glycol, and release a large amount of reactive oxygen species through ultrasonic activation, which can bactericidal and induce necrosis on tumor cells.
It improves the generation efficiency and water solubility of reactive oxygen species, enhances the clinical transformation prospects of manganese-doped iron oxide nanoparticles, and provides more efficient anti-tumor treatment effects, especially in the treatment of triple-negative breast cancer.
Smart Images

Figure CN118976105A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of ultrasound-triggered sonodynamic therapy, and in particular relates to an application of manganese-doped iron oxide nanoparticles in the preparation of anti-tumor drugs and the anti-tumor drugs. Background Art
[0002] In the past decade, the incidence of breast cancer has continued to grow worldwide, and its heterogeneity, drug resistance, and metastasis are still the main causes of death in women. Triple-negative breast cancer (TNBC), as one of the types of breast cancer, has multiple subtypes and shows high heterogeneity. Compared with other types of breast cancer, TNBC has the characteristics of early recurrence and metastasis, high mortality, and extremely poor prognosis, and it is not sensitive to the main treatment method-chemotherapeutic drugs. However, the current treatment methods, such as chemotherapy, radiotherapy, and chemodynamic therapy (CDT), are not effective, are prone to drug resistance, and have large toxic side effects, making it difficult to inhibit its metastasis and recurrence. Therefore, there is an urgent need for new treatment methods to improve the treatment effect of breast cancer.
[0003] Ultrasound (US)-triggered sonodynamic therapy (SDT) has attracted extensive attention from multiple disciplines in recent years as a non-invasive treatment method. As a new type of material in the field of sonochemistry, sonosensitizers can be activated by low-intensity ultrasound and efficiently produce toxic reactive oxygen species (ROS) at a fixed point. They can not only kill bacteria and resist toxicity under the action of ultrasound, but also effectively induce necrosis and apoptosis of tumor cells, and more efficiently play the role of ultrasound in anti-cancer and antibacterial. Its basic principle: when ultrasound of a certain power activates sonosensitizers, the absorbed energy undergoes electronic transition, which is excited from a low-energy state to a high-energy state, and a large amount of ROS is released when it returns to a low-energy state. ROS acts on the DNA of tumor cells, changes the DNA base sequence and DNA configuration of tumor cells, destroys the DNA template function, and then inhibits or kills tumor cells. At the same time, it damages the cell membrane of tumor cells to cause cell necrosis, damages the cell nucleus and mitochondria to cause cell apoptosis, and damages the endoplasmic reticulum to induce cell autophagy and death, thereby achieving the purpose of anti-tumor. Compared with phototherapy, SDT provides more opportunities, such as deeper tissue penetration and fewer side effects.
[0004] At present, typical sonosensitizers mainly include organic sonosensitizers represented by hematoporphyrin and its complexes and inorganic sonosensitizers represented by titanium dioxide and its complexes. However, some inherent deficiencies of sonosensitizers have seriously limited their clinical application. For example, the phototoxicity, poor water solubility, insufficient utilization rate and hypoxic tumor microenvironment of organic sonosensitizers have become bottlenecks in clinical transformation, and the efficiency of reactive oxygen production of inorganic sonosensitizers is low.
[0005] Therefore, in order to accelerate the clinical transformation of SDT, it is urgent to develop sonosensitizers that can be clinically transformed. Summary of the invention
[0006] In response to the above technical problems, the present invention provides an application of manganese-doped iron oxide nanoparticles in the preparation of anti-tumor drugs and anti-tumor drugs. The surface of the manganese-doped iron oxide nanoparticles is adsorbed with a non-ionic surfactant to increase the hydrophilicity. Under the excitation of ultrasound, a large amount of reactive oxygen is released to act on tumor cells, and the anti-tumor drugs can be used to prepare anti-tumor drugs.
[0007] To achieve the above object, the technical solution of the present invention is:
[0008] A use of manganese-doped iron oxide nanoparticles in the preparation of anti-tumor drugs, wherein a non-ionic surfactant is adsorbed on the surface of the manganese-doped iron oxide nanoparticles, and ultrasound of preset power activates the manganese-doped iron oxide nanoparticles to release active oxygen, which is configured to kill bacteria, resist toxins and induce tumor cell necrosis.
[0009] Preferably, the concentration of the manganese-doped iron oxide nanoparticles is 12.5-2000 μg / mL.
[0010] Preferably, the manganese-doped iron oxide nanoparticles are prepared by hydrothermal synthesis.
[0011] Preferably, the method for preparing the manganese-doped iron oxide nanoparticles comprises: mixing an iron salt and a manganese salt to prepare a mixed solution, adding a nonionic surfactant to the mixed solution, and then reacting in an autoclave at a temperature of 120° C. for 18-24 hours.
[0012] Preferably, 243.3 mg of Fe(NO3)3·9H2O and 34-1700 μL of 50% Mn(NO3)2 are added into 30-35 mL of distilled water to prepare a mixed solution.
[0013] Preferably, the nonionic surfactant is polyethylene glycol.
[0014] Based on the same inventive concept, the present invention also provides an anti-tumor drug for sonodynamic therapy, wherein the anti-tumor drug is prepared from manganese-doped iron oxide nanoparticles, and a non-ionic surfactant is adsorbed on the surface of the manganese-doped iron oxide nanoparticles.
[0015] Preferably, the manganese-doped iron oxide nanoparticles are prepared by hydrothermal synthesis, specifically comprising: mixing iron salt and manganese salt to prepare a mixed solution, adding a non-ionic surfactant to the mixed solution, and then reacting in an autoclave at a temperature of 120° C. for 18-24 hours.
[0016] Preferably, 243.3 mg of Fe(NO3)3·9H2O and 34-1700 μL of 50% Mn(NO3)2 are added into 30-35 mL of distilled water to prepare a mixed solution.
[0017] Preferably, the nonionic surfactant is polyethylene glycol.
[0018] Preferably, the concentration of the manganese-doped iron oxide nanoparticles is 12.5-2000 μg / mL.
[0019] Due to the adoption of the above technical solution, the present invention has the following advantages and positive effects compared with the prior art:
[0020] The present invention provides manganese-doped iron oxide nanoparticles, the surface of which is adsorbed with a nonionic surfactant, such as polyethylene glycol, which increases the hydrophilicity of the manganese-doped iron oxide nanoparticles and further increases the water solubility; the iron oxide has a suitable band gap, manganese doping reduces the band gap width, and introduces more oxygen vacancies into the iron oxide, thereby improving the efficiency of generating ROS; and the iron oxide has a wide range of sources and low toxicity, so the manganese-doped iron oxide nanoparticles of the present invention have an application prospect of clinical transformation in anti-tumor. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 ac are the microscopic characterizations of the Mn-Fe2O3NCs of the embodiment of the present invention, wherein d is the lattice analysis of Mn-Fe2O3NCs; e is the element mapping diagram of Mn, Fe and O in Mn-Fe2O3NCs;
[0022] Figure 2 is a particle size diagram of Mn-Fe2O3 NCs according to an embodiment of the present invention;
[0023] Figure 3 XRD pattern of Mn-Fe2O3NCs of the embodiment of the present invention;
[0024] Figure 4 The mechanism analysis of the generation of ROS by Mn-Fe2O3NCs in the embodiment of the present invention, wherein a is the UV-visible spectra of Fe2O3NCs and Mn-Fe2O3NCs, b is the band gap diagram of Fe2O3NCs and Mn-Fe2O3NCs, c is the Mott-Schottky diagram of Fe2O3NCs and d is the Mn-Fe2O3NCs, e is the mechanism diagram of the generation of ROS by Mn-Fe2O3NCs under the action of US, and f is the electrochemical impedance diagram of Fe2O3NCs and Mn-Fe2O3NCs;
[0025] Figure 5is the oxygen vacancy intensity, where a is the oxygen vacancy intensity of Fe2O3 NCs, and b is the oxygen vacancy intensity of Mn-Fe2O3 NCs;
[0026] Figure 6 The intensity of the hydroxyl radical peak generated for different groups;
[0027] Figure 7 The evaluation results of the release of ROS by Mn-Fe2O3NCs under ultrasonic excitation in the embodiments of the present invention, including (a) the absorption spectra of MB in different groups after US irradiation for 12 minutes, (b) the absorption spectra of MB changing with time under Mn-Fe2O3NCs+US treatment; (c) the absorbance of MB at 662nm in the control group, Mn-Fe2O3NCs group, US group and Mn-Fe2O3NCs+US group;
[0028] Figure 8 The intracellular evaluation of the present invention is shown in Figure 1, where a is the viability of L929 cells and MDA cells treated with different concentrations of Mn-Fe2O3NCs (n=5, mean ± SD), b is the survival rate of MDA cells in each group after different treatments (n=4, mean ± SD), and c is the fluorescence image of DCFH-DA stained MDA cells after different treatments (green: ROS generation, US: 1.0 MHz, duty cycle 30%, 1 W / cm 2 , 2 min), d is the cell activity of MDA cells after different treatments (US: 1.0 MHz, duty cycle 30%, 1 W / cm 2 , 2 min), e is the mitochondrial membrane potential of MDA cells under different treatments (US: 1.0 MHz, duty cycle 30%, 1 W / cm 2 , 2min);
[0029] Fig. 9 The anti-tumor evaluation of Mn-Fe2O3NCs in the present invention in the example of the animal mice, a is a schematic diagram of the mouse treatment route, b is the change of tumor volume in each group of mice according to the initial weight of mice, c is the change of tumor volume in each group of mice during the 10-day treatment period (T test, *p<0.05, **p<0.01, ***p<0.001), d is the tumor weight and images of different groups after the mouse tumors were removed on the 10th day, and e is a representative image of each group of tumor-bearing mice collected on the 0th day and the 10th day;
[0030] Note: In the above drawings, except for Figure 2 , Mn-Fe2O3 in other figures all represent Mn-Fe2O3 NCs prepared in the examples. DETAILED DESCRIPTION
[0031] Inorganic sonosensitizers have the advantages of high stability and high tumor enrichment rate, but the high energy required for carrier excitation due to the wide band gap and the electrons (e) generated by the narrow band gap under US irradiation are - )-hole (h + ) Rapid recombination makes the production efficiency of reactive oxygen species lower.
[0032] The present invention selects iron oxide with a suitable band gap, reduces its band gap width by manganese doping, introduces more oxygen vacancies, increases the efficiency of ROS generation, and uses non-ionic surfactant modification to increase hydrophilicity and biosafety, so that manganese-doped iron oxide nanoparticles can be used in the preparation of anti-tumor drugs, especially for triple-negative breast cancer.
[0033] The following is a further detailed description of the application of manganese-doped iron oxide nanoparticles in the preparation of anti-tumor drugs and the anti-tumor drugs proposed by the present invention in conjunction with the accompanying drawings and specific examples. The advantages and features of the present invention will become more clear based on the following description.
[0034] 1. Preparation of manganese-doped iron oxide nanoparticles:
[0035] First, 243.3 mg of Fe(NO3)3·9H2O and 34 μL of 50% Mn(NO3)2 were added to 35 mL of distilled water, and then PEG (polyethylene glycol, molecular weight 20000 Da) was added to the mixed solution. After stirring for 2 h, the solution was reacted in a 50 mL autoclave at 120 ° C for 24 h. Finally, the solution was centrifuged and washed alternately with water and ethanol three times to obtain manganese-doped iron oxide nanoparticles (hereinafter referred to as Mn-Fe2O3 NCs).
[0036] Pure Fe2O3 NCs group: First, 243.3 mg of Fe(NO3)3·9H2O was added to 35 mL of distilled water, and then PEG (polyethylene glycol, molecular weight 20000 Da) was added to the mixed solution. After stirring for 2 h, the solution was reacted in a 50 mL autoclave at 120 °C for 24 h. Finally, the solution was centrifuged and washed alternately with water and ethanol three times to obtain pure Fe2O3 NCs.
[0037] 2. Microstructure and crystal structure
[0038] The prepared Mn-Fe2O3 NCs were examined by transmission electron microscopy, and the microstructure was as follows: Figure 1 As shown, ac is the photograph of the microscopic morphology of Mn-Fe2O3 NCs. It can be seen from the figure that Mn-Fe2O3 NCs are flaky and have PEG on the surface. d is the lattice analysis of Mn-Fe2O3 NCs. It can be seen from the figure that the lattice distance of Mn-Fe2O3 NCs is about 0.252nm, which is consistent with the standard crystal phase of Fe2O3. Figure 1 Figure e is the element mapping diagram of Mn, Fe and O in Mn-Fe2O3 NCs, indicating that Mn, Fe and O elements are uniformly distributed in Mn-Fe2O3 NCs, proving that Mn element is successfully doped into Fe2O3.
[0039] The particle size of nanomaterials has an important influence on their circulation time in the blood and the degree of enrichment in tumor sites. PEG can improve the biosafety of nanoparticles and reduce the surface tension of liquids to improve the size and stability of nanoparticles. During the reaction process, Mn-Fe2O3 was modified with a high molecular weight non-ionic surfactant PEG to improve the hydrophilicity of the material. Compared with the one without PEG, the size of Mn-Fe2O3 NCs became smaller. Figure 2 Dynamic light scattering (DLS) showed that the average hydrated particle size of Mn-Fe2O3 NCs was about 68nm, and its nanoparticles were concentrated between 43nm and 255nm, which is conducive to the sustained effect of Mn-Fe2O3 NCs at the tumor site.
[0040] Figure 3 The XRD diffraction pattern of Mn-Fe2O3 NCs shows a high match with the standard characteristic peak of Fe2O3 (PDF#33-0664). At the same time, the diffraction peak of Fe2O3 doped with Mn has no obvious difference with Fe2O3, which may be due to the low doping amount of Mn. The above results show that Mn-Fe2O3 NCs are successfully prepared.
[0041] 3. Catalytic mechanism of Mn-Fe2O3 NCs
[0042] Fe2O3 is a common N-type direct bandgap semiconductor material with narrow bandgap characteristics. The effect of Mn doping on the bandgap and valence band position of Fe2O3 was studied by UV-vis spectroscopy and electrochemical workstation testing. The UV spectra of pure Fe2O3 NCs and Mn-Fe2O3 NCs were measured by UV-vis spectroscopy. The results are shown in Figure 4 As shown in a, the corresponding band gap curve is drawn through analysis and calculation, as shown in Figure 4 As shown in (b), the band gap of Mn-Fe2O3 NCs is 1.94 eV, which is significantly narrower than that of Fe2O3. - The energy required to excite from the valence band (VB) to the conduction band (CB) is significantly reduced. Then, the Mott-Schottky (MS) curve and electrochemical impedance spectroscopy (EIS) curve of pure Fe2O3 NCs and Mn-Fe2O3 NCs were tested by electrochemical workstation. Figure 4In Figures c and d, according to the band gap value obtained from the UV-visible spectrum (UV-vis) and the flat band value obtained from the Mott-Schottky (MS) curve, the VB potentials of pure Fe2O3 NCs and Mn-Fe2O3 NCs are 2.17 eV and 2.49 eV (vs NHE), respectively. - / ·OH correction (2.02-2.4eV vs. NHE). This indicates that under US irradiation, the Mn-Fe2O3 NCs group can undergo electron separation and generate ·OH ( Figure 4 In addition, Figure 4 The f in the figure indicates that the Mn-Fe2O3NCs group has a lower charge transfer resistance (R ct ). Usually the EIS Nyquist plot can be used to determine the charge separation and transfer efficiency, such as Figure 4 As shown in f, the smaller the diameter of the semicircle in the high-frequency region, the higher the charge transfer resistance (R ct ) is lower, the higher the catalytic activity of the material. This shows that the introduction of Mn element is beneficial to promote the process of electron generation.
[0043] Electron spin resonance (ESR) technology can be used to study the presence of oxygen defects in nanomaterials and their ability to generate ROS. The enhancement of vacancies can reduce the energy band width and reaction energy barrier and improve catalytic activity. The vacancies of Fe2O3 NCs and Mn-Fe2O3 NCs were determined by EPR method. The results are as follows: Figure 5 As shown in the figure, characteristic ESR resonances were observed for the two materials at around g = 2.1 and g = 2.005, respectively. At the same time, it was found that the oxygen vacancy signal intensity of manganese-doped Fe2O3 (Mn-Fe2O3 NCs) was almost 4 times that of pure Fe2O3, indicating that manganese doping introduced more oxygen vacancies into Fe2O3.
[0044] To prove that only under US excitation can Mn-Fe2O3 NCs undergo electron separation and generate ·OH, Figure 6 The intensity of the hydroxyl free peak generated by different groups is shown. The blank group contains only water, the US group contains US irradiated water, and the Fe2O3 group contains undoped Fe2O3 NCs. Figure 6 It can be seen that only in US-irradiated Mn-Fe2O3 NCs, the ·OH peak is the strongest, while there is almost no ·OH peak in the others.
[0045] In conclusion, Mn doping not only reduces the energy required for electron excitation but also enhances the separation and transport efficiency of charge carriers under US irradiation. Therefore, Mn-Fe2O3 NCs have highly efficient SDT catalytic performance.
[0046] 4. Release ROS detection
[0047] MB was used to detect the ROS generation efficiency of Mn-Fe2O3 NCs. -2 ) conditions, 1 mL of Mn-Fe2O3 NCs (0, 200 μg / mL) solution was prepared, mixed with 1 mL PBS and 4 mL MB (5 μg / mL) in sequence, and then the absorbance changes of the solution at different times in the range of 500nm-800nm were tested by ultraviolet spectrophotometer (UV-vis) to prove the generation of ROS. For the other three groups of tests, except for the following changes, other conditions remained the same. Control group: 1 mL of Mn-Fe2O3 NCs was replaced with 1 mL PBS, and no US treatment was given. US group: 1 mL of Mn-Fe2O3 NCs was replaced with 1 mL PBS. Mn-Fe2O3 NCs group: no US treatment was given. The above tests were repeated three times.
[0048] The results are as follows Figure 7 As shown in the figure, under US irradiation, the absorbance of MB gradually decreased with time, and its absorbance value was reduced by about half at around 12 minutes, indicating that its Mn-Fe2O3 NCs can release a large amount of ROS.
[0049] 5. In vitro experimental evaluation
[0050] The effects of different concentrations of Mn-Fe2O3 NCs and different treatments on cell viability were evaluated using a standard CCK-8 assay.
[0051] Effects of different concentrations of Mn-Fe2O3 NCs on cell viability: MDA-MB-231 (MDA, a breast cancer cell) and L929 (fibroblasts, normal cells) cells were cultured at 1×10 4 The density of 100 μg / mL was inoculated in a 96-well plate and cultured at 37°C and 5% for 24 h. Then, different concentrations of Mn-Fe2O3 NCs (0, 12.5, 25, 50, 100, 200 μg / mL) were incubated with the cells for 24 h. In addition, MDA cells were divided into 4 groups (n=4, each group) for subsequent experimental treatments.
[0052] Effects of different treatments on cell viability: (1) control group; (2) US; (3) Mn-Fe2O3 NCs; (4) Mn-Fe2O3 NCs + US. Groups (1) and (2) used the original culture medium, while groups (3) and (4) replaced the original culture medium with a culture medium containing 200 μg / mL Mn-Fe2O3 NCs. After 12 h of culture, groups (2) and (4) were treated with US (1.0 MHz, 30% duty cycle, 1.0 W·cm-2 ) for 2 min, and all groups of cells were cultured again for 12 h.
[0053] Finally, after treating the cells with CCK-8 in both experiments, the OD value of each well was measured at 450 nm using an ELISA reader. Figure 8 As shown in a and b in Figure 1, it can be seen from Figure 1 that although different concentrations of Mn-Fe2O3 NCs were added to the culture medium, the cell activity of each group was not much different when US was not performed, and it was not much different from the cell activity of adding 0 Mn-Fe2O3 NCs, indicating that even if Mn-Fe2O3 NCs were used for treatment without US stimulation, the activity of normal cells and cancer cells would not be affected, which also shows that Mn-Fe2O3 NCs had no effect on cell growth and proliferation. Combined with Figure 1, it can be seen that only when Mn-Fe2O3 NCs and US were stimulated, ROS was released to reduce the activity of cells.
[0054] Different staining reagents were used to evaluate the changes in cells in different groups after different treatments. First, MDA cells were seeded at 5×10 4 The density of 100 μg / mL was inoculated in a 24-well plate and cultured at 37°C and 5% for 24 h to allow the cells to fully adhere to the wall. Then, the MDA cells were divided into 4 groups: (1) control group; (2) US; (3) Mn-Fe2O3 NCs; (4) Mn-Fe2O3 NCs+US.
[0055] The DCFH-DA reagent was used to evaluate the intracellular ROS content. Groups (3) and (4) were incubated with 200 μg / mL of Mn-Fe2O3 NCs and cells. After 6 h of incubation, cells were stained with DCFH-DA for 30 min at 37°C in the dark. Then, groups (2) and (4) were treated with US (1.0 MHz, 30% duty cycle, 1.0 W·cm -2 ) for 2 min. Then, the cells were washed several times with PBS. Finally, the cells were imaged using a confocal fluorescence microscope. DCF showed green fluorescence (λ ex =488nm,λ em =525nm), the results are as follows Figure 8 As shown in c.
[0056] Calcein-AM / PI double staining reagent was used to evaluate the live / dead status of cells. Groups (3) and (4) were incubated with Mn-Fe2O3 NCs containing 200 μg / mL Mn-Fe2O3 NCs. After 5 h of culture, groups (2) and (4) were treated with US (1.0 MHz, 30% duty cycle, 1.0 W·cm -2) for 2 min. Culture again for 5 h, use PBS solution containing Calcein-AM (10 μL) and PI (10 μL) to stain the cells for 30 min at 37°C in the dark, and then wash the cells several times with PBS. Finally, use confocal fluorescence microscopy to take cell images. Live / dead cells show green fluorescence / red fluorescence respectively under confocal fluorescence microscopy. The results are shown in Figure 8 As shown in (d), groups (1), (2), and (3) all showed green fluorescence, indicating that they were living cells, and group (4) showed red fluorescence, indicating that the cells were no longer active. This further demonstrated that the Mn-Fe2O3 NCs released a large amount of ROS induced necrosis and apoptosis of MBA cells induced by ultrasonic laser.
[0057] In addition, JC-1 reagent was used to evaluate the changes in mitochondrial membrane potential of cells to explore the possible cause of cell death. Groups (3) and (4) were incubated with Mn-Fe2O3 NCs containing 200 μg / mL Mn-Fe2O3 NCs. After 12 h of culture, groups (2) and (4) were treated with US (1.0 MHz, 30%, duty cycle, 1.0 W·cm -2 ) irradiated for 2 min. Cultured again for 12 h, the cells were stained with JC-1 staining solution for 30 min, and then washed several times with JC-1 working buffer. Finally, the cells were imaged using a confocal fluorescence microscope within 30 min. The results are shown in Figure 8 As shown in Figure e, in normal mitochondria, JC-1 appears as aggregates with red fluorescence, while the mitochondria of MDA cells treated with Mn-Fe2O3 NCs+US show green fluorescence, indicating a decrease in mitochondrial membrane potential ( Figure 8 e). It is very likely that Mn-Fe2O3 NCs under US stimulation produced ROS-induced mitochondrial damage. And mitochondrial damage may inhibit the respiration of tumor cells, slow down oxygen consumption, enhance the auxiliary enhancement of SDT treatment effect, and further lead to tumor cell death.
[0058] 6. In vivo animal anti-tumor evaluation
[0059] A tumor model was established in the subcutaneous axilla of healthy female nude mice at 5 weeks of age. The nude mice bearing MDA tumors were randomly divided into 4 groups (n=4, each group): (1) control group; (2) US; (3) Mn-Fe2O3 NCs; (4) Mn-Fe2O3 NCs+US. Each mouse in group (1) and group (2) was intravenously injected with PBS, and each mouse in group (3) and group (4) was intravenously injected with 200 μL of Mn-Fe2O3 NCs (2 mg / mL). Groups (2) and (4) were treated with US (1.0 MHz, 50% duty cycle, 1.0 W·cm) at 12 h and 36 h, respectively. -2During the treatment period, the size of the tumor and the weight of the mice were measured every other day for 10 days to evaluate the therapeutic effect. Figure 8 The results are shown in Fig. 9 As shown, Fig. 9 b is the relative change of tumor volume in each group based on initial body weight, c is the change of tumor volume in each group on day 10; d is the tumor weight and image of different groups after mouse tumors were removed on day 10; e is the representative image of tumor-bearing mice in each group collected on day 0 and day 10. During the 10-day treatment period, the body weight of all mice did not change significantly, indicating that US irradiation did not cause significant harm to mice during treatment, and Mn-Fe2O3 NCs also have good biosafety. Fig. 9 From the results from b to e in the figure, by comparing the size of the tumors of the four groups of mice on the first and tenth days, we can see from the figure that the tumors in the control group and the US group grew rapidly, indicating that US irradiation had almost no inhibitory effect on tumor growth. Due to the Fenton effect of Mn-Fe2O3 NCs in the tumor microenvironment, Mn-Fe2O3 NCs showed a certain inhibitory effect on tumors. Mn-Fe2O3 NCs can produce abundant ROS when irradiated by US. Therefore, its significant inhibitory effect on tumors can be seen in the Mn-Fe2O3 NCs+US group. It can be further explained that the ROS released by Mn-Fe2O3 NCs under the stimulation of US can induce the death of tumor cells, and thus has the application of preparing anti-tumor drugs.
[0060] The calculation formula of tumor is as follows: V = a × b 2 / 2 (a: maximum length of the tumor, b: minimum length of the tumor). Animal experiments were conducted in accordance with the Care and Use of Laboratory Animals.
[0061] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Even if various changes are made to the present invention, if these changes fall within the scope of the claims of the present invention and their equivalents, they still fall within the protection scope of the present invention.
Claims
1. Use of manganese-doped iron oxide nanoparticles in the preparation of anti-tumor drugs, characterized in that: A nonionic surfactant is adsorbed on the surface of the manganese-doped iron oxide nanoparticles, and ultrasound of a preset power activates the manganese-doped iron oxide nanoparticles, and the manganese-doped iron oxide nanoparticles release reactive oxygen species, which are configured to induce tumor cell necrosis.
2. The use of manganese-doped iron oxide nanoparticles according to claim 1 in the preparation of anti-tumor drugs, characterized in that: The concentration of the manganese-doped iron oxide nanoparticles is 12.5-2000 μg / mL.
3. The use of manganese-doped iron oxide nanoparticles according to claim 1 in the preparation of anti-tumor drugs, characterized in that: The manganese-doped iron oxide nanoparticles are prepared by hydrothermal synthesis, which specifically includes: mixing iron salt and manganese salt to prepare a mixed solution, adding a non-ionic surfactant to the mixed solution, and then reacting in an autoclave at a temperature of 120° C. for 18-24 hours.
4. The use of manganese-doped iron oxide nanoparticles in the preparation of anti-tumor drugs according to claim 3, characterized in that: The mixed solution is prepared by adding 243.3 mg of Fe(NO3)3·9H2O and 34-1700 μL of Mn(NO3)2 with a mass fraction of 50% into 30-35 mL of distilled water.
5. Use of manganese-doped iron oxide nanoparticles according to claim 1 or 3 in the preparation of anti-tumor drugs, characterized in that: The nonionic surfactant is polyethylene glycol.
6. An anti-tumor drug for sonodynamic therapy, characterized in that: The anti-tumor drug is prepared from manganese-doped iron oxide nanoparticles, and non-ionic surfactant is adsorbed on the surface of the manganese-doped iron oxide nanoparticles.
7. The anti-tumor drug for sonodynamic therapy according to claim 6, characterized in that: The manganese-doped iron oxide nanoparticles are prepared by hydrothermal synthesis, which specifically includes: mixing iron salt and manganese salt to prepare a mixed solution, adding a non-ionic surfactant to the mixed solution, and then reacting in an autoclave at a temperature of 120° C. for 18-24 hours.
8. The use of manganese-doped iron oxide nanoparticles in the preparation of anti-tumor drugs according to claim 7, characterized in that: The mixed solution is prepared by adding 243.3 mg of Fe(NO3)3·9H2O and 34-1700 μL of Mn(NO3)2 with a mass fraction of 50% into 30-35 mL of distilled water.
9. Use of manganese-doped iron oxide nanoparticles according to claim 6 or 7 in the preparation of anti-tumor drugs, characterized in that: The nonionic surfactant is polyethylene glycol.
10. The use of manganese-doped iron oxide nanoparticles in the preparation of anti-tumor drugs according to claim 6, characterized in that: The concentration of the manganese-doped iron oxide nanoparticles is 12.5-2000 μg / mL.
Citation Information
Cited By
Application of Mn-RuO2 in preparation of medicine for treating cancer
CN121943962A
